Clinical Trial Visits in the Age of COVID-19: Implementation of Research Participant Safety Measures.

ABSTRACT: The COVID-19 pandemic is having a major impact on how current clinical trials are being conducted in the U.S. Researchers have experienced the effects of COVID-19 through the halting and delaying of clinical trials, the lack of personal protection equipment (PPE), the closing of clinical sites, and a decrease in participant recruitment. Many clinical trials will have more missing data because of a participant's inability to attend in-person visits, discontinuation of trial activities, or interruption of time-sensitive study collection data due to COVID-19. All of these events affect the data quality of trials. Government agencies such as the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH) have issued recommendati

SUBMITTER: Krueger KJ 

PROVIDER: S-EPMC8136620 | biostudies-literature | 2021 Apr-Jun

REPOSITORIES: biostudies-literature